Taxes | Period [Axis] |
---|
2016-01-01 - 2016-12-31 |
---|
Taxes | |
Schedule of components of (loss) gain before taxes from continuing operations |
|
|
|
Year Ended December 31,
|
|
|
|
|
2015
|
|
|
2016
|
|
Domestic
|
|
|
|
$ |
(2,520) |
|
|
|
|
$ |
(2,011) |
|
|
Foreign
|
|
|
|
|
(13,966) |
|
|
|
|
|
(11,763) |
|
|
Loss from continuing operations before taxes
|
|
|
|
$ |
(16,486) |
|
|
|
|
$ |
(13,774) |
|
|
|
|
Schedule of benefit for income taxes from continuing operations |
|
|
|
Year Ended December 31,
|
|
|
|
|
2015
|
|
|
2016
|
|
Current – domestic
|
|
|
|
$ |
— |
|
|
|
|
$ |
— |
|
|
Current – foreign
|
|
|
|
|
2,144 |
|
|
|
|
|
1,983 |
|
|
Current – total
|
|
|
|
|
2,144 |
|
|
|
|
|
1,983 |
|
|
Deferred – domestic
|
|
|
|
|
— |
|
|
|
|
|
— |
|
|
Income tax benefit
|
|
|
|
$ |
2,144 |
|
|
|
|
$ |
1,983 |
|
|
|
|
Schedule of reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory federal tax rate to loss before income taxes |
|
|
|
Year Ended December 31,
|
|
|
|
|
2015
|
|
|
2016
|
|
Loss from continuing operations before taxes
|
|
|
|
$ |
(16,486) |
|
|
|
|
$ |
(13,774) |
|
|
Income tax expense computed at statutory federal tax rate
|
|
|
|
|
(5,605) |
|
|
|
|
|
(4,683) |
|
|
Disallowed expenses and non-taxable income
|
|
|
|
|
27 |
|
|
|
|
|
12 |
|
|
Loss surrendered to generate R&D credit
|
|
|
|
|
2,479 |
|
|
|
|
|
1,945 |
|
|
Additional research and development tax relief
|
|
|
|
|
(3,402) |
|
|
|
|
|
(2,827) |
|
|
Change in valuation allowance
|
|
|
|
|
(4,189) |
|
|
|
|
|
2,029 |
|
|
Foreign items, including change in tax rates, and other
|
|
|
|
|
6,882 |
|
|
|
|
|
1,238 |
|
|
Other foreign items
|
|
|
|
|
1,664 |
|
|
|
|
|
303 |
|
|
|
|
|
|
$ |
(2,144) |
|
|
|
|
$ |
(1,983) |
|
|
|
|
Schedule of significant components of the entity's deferred tax assets |
|
|
|
Year Ended December 31,
|
|
|
|
|
2015
|
|
|
2016
|
|
Net operating loss carryforwards
|
|
|
|
$ |
41,003 |
|
|
|
|
$ |
42,851 |
|
|
Depreciation, amortization and impairment of property and equipment
|
|
|
|
|
101 |
|
|
|
|
|
137 |
|
|
Stock options
|
|
|
|
|
2,193 |
|
|
|
|
|
2,365 |
|
|
Research and development credits
|
|
|
|
|
4,021 |
|
|
|
|
|
4,021 |
|
|
Other
|
|
|
|
|
38 |
|
|
|
|
|
— |
|
|
Deferred tax assets
|
|
|
|
|
47,356 |
|
|
|
|
|
49,374 |
|
|
Valuation allowance for deferred tax assets
|
|
|
|
|
(47,356) |
|
|
|
|
|
(49,374) |
|
|
Net deferred tax assets
|
|
|
|
$ |
— |
|
|
|
|
$ |
— |
|
|
|
|